| Literature DB >> 28336767 |
Xin-Man Dou1,2, Hui-Juan Cheng2,3, Ling Meng2, Lin-Lin Zhou4, Yi-Hong Ke4, Li-Ping Liu5, Yu-Min Li6,2,3.
Abstract
The aim of the present study is to investigate association between septic shock (SS) and angiotensin I-converting enzyme (ACE) single nucleotide polymorphisms (SNPs). From October 2009 to December 2016, 238 SS patients and 242 healthy individuals were selected for our study. ACE activity was detected, ACE rs4291 and rs4646994 polymorphisms were detected using PCR-restriction fragment length polymorphism (PCR-RFLP). The Kaplan-Meier survival curve was employed to evaluate the association between ACE SNPs and patients' survival and univariate and multivariate analyses to estimate risk factors for SS. ACE activity in the case group was increased in comparison with the control group. Allele and genotype frequencies of rs4291 and rs4646994 were different between the case and control groups. The TT genotype frequency of the rs4291 polymorphisms and the DD genotype of the rs4646994 polymorphisms of the case group were higher than those in the control group. The AT and TT genotypes indicated a significant elevation of ACE activity than the AA genotype, while a significant decline was found in the DI and II genotypes in comparison with the DI genotype. Patients with TT or DD genotypes had increased fatality rate within 7 and 30 days when compared with those with non-TT or non-DD genotypes. Lower sepsis-related organ failure assessment (SOFA) scores, rs4291, serum ACE and rs4646994 were all considered as risky factors for SS patients. The study demonstrates that TT genotype of rs4291 or DD genotype of rs4646994 may be indicative of a higher risk of SS and a poorer prognosis in SS patients.Entities:
Keywords: Angiotensin I-converting enzyme; Prognosis; Septic shock; Single nucleotide polymorphisms
Mesh:
Substances:
Year: 2017 PMID: 28336767 PMCID: PMC5408661 DOI: 10.1042/BSR20170145
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1Enzyme electrophoresis of ACE rs4291/rs4646994
(A) Enzyme electrophoresis of rs4291; (B) enzyme electrophoresis of rs4646994; M, marker.
Baseline characteristics of patients with SS
| Characteristic | Case group ( | Control group ( | |
|---|---|---|---|
| Age (years) | 52.09 ± 7.06 | 52.96 ± 5.32 | 0.128 |
| Gender (male/female) | 133/105 | 128/114 | 0.511 |
| APACHE II | 32.10 ± 12.37 | ||
| SOFA | 9.02 ± 2.77 | ||
| Source of infection ( | |||
| Lung | 73 (43.28) | ||
| Abdomen | 53 (24.37) | ||
| Peripheral blood | 49 (30.67) | ||
| Wounds | 28 (14.71) | ||
| Other parts | 35 (15.97) | ||
| Infectious bacteria | |||
| G+ bacteria | 69 (43.70) | ||
| G− bacteria | 93 (74.37) | ||
| Mixed infection | 55 (28.57) | ||
| Unknown infection | 21 (10.08) | ||
| ACE activity (U/l) | 53.59 ± 6.48 | 46.81 ± 5.92 | < 0.001 |
HWE test of two ACE SNPs
| SNP | Genotype | Case group | Control group | ||||||
|---|---|---|---|---|---|---|---|---|---|
| O | E | χ2 | O | E | χ2 | ||||
| rs4291 | 0.102 | 0.95 | 1.385 | 0.5 | |||||
| AA | 59 | 60 | 105 | 99 | |||||
| AT | 122 | 119 | 100 | 112 | |||||
| TT | 57 | 59 | 37 | 31 | |||||
| 0.308 | 0.857 | 0.843 | 0.656 | ||||||
| rs4646994 | DD | 52 | 49 | 35 | 32 | ||||
| DI | 112 | 118 | 102 | 112 | |||||
| II | 74 | 71 | 105 | 98 | |||||
E, expected number; O, observed number.
Frequencies of genotypes and alleles of two ACE SNPs in the case and control groups
| Genotype/allele | Control group | Case group | χ2 | |
|---|---|---|---|---|
| ( | ( | |||
| rs4291 | ||||
| AA | 105 (43.39) | 59 (24.79) | Ref. | |
| AT | 100 (41.32) | 122 (51.26) | 13.64 | <0.001 |
| TT | 37 (15.29) | 57 (23.95) | 14.69 | <0.001 |
| A | 310 (64.05) | 240 (50.42) | Ref. | |
| T | 174 (35.95) | 236 (49.58) | 18.22 | <0.001 |
| rs4646994 | ||||
| DD | 35 (14.46) | 52 (21.85) | 7.976 | 0.005 |
| DI | 102 (42.80) | 112 (47.06) | 4.727 | 0.03 |
| II | 105 (43.39) | 74 (31.09) | Ref. | |
| D | 172 (35.53) | 216 (45.37) | 9.651 | 0.002 |
| I | 312 (64.47) | 260 (54.63) | Ref. |
Ref., reference, i.e. AA/II genotype as the controls.
Correlation of two ACE SNPs and ACE activity
| Genotype/allele | ACE activity (U/l) | |
|---|---|---|
| rs4291 | ||
| AA | 49.75 ± 5.47 | |
| AT | 53.85 ± 5.18 | <0.001 |
| TT | 57.00 ± 7.81 | <0.001 |
| rs4646994 | ||
| DD | 60.05 ± 5.06 | |
| DI | 53.27 ± 5.45 | <0.001 |
| II | 49.53 ± 5.17 | <0.001 |
Frequencies of genotypes and alleles of two ACE SNPs in the death and survival groups
| Genotype/allele | Survival group | Death group | χ2 | |
|---|---|---|---|---|
| ( | ( | |||
| rs4291 | ||||
| AA | 57 (34.55) | 2 (7.69) | Ref. | |
| AT | 86 (52.12) | 36 (49.31) | 16.36 | <0.001 |
| TT | 22 (13.33) | 35 (34.62) | 44.92 | <0.001 |
| A | 200 (60.61) | 40 (27.40) | Ref. | |
| T | 130 (39.39) | 106 (72.60) | 44.65 | <0.001 |
| rs4646994 | ||||
| DD | 20 (12.12) | 32 (43.84) | 31.7 | <0.001 |
| DI | 81 (49.10) | 31 (42.47) | 5.2 | 0.023 |
| II | 64 (38.78) | 10 (13.69) | Ref. | |
| D | 121 (36.67) | 95 (65.07) | 32.94 | <0.001 |
| I | 209 (63.33) | 51 (34.93) | Ref. |
Ref., reference, i.e. A/I as the controls.
Haplotype analysis of ACE rs4646994 and rs4291 polymorphisms
| Haplotype | Case group | Control group | OR | 95% CI | ||
|---|---|---|---|---|---|---|
| A | I | 130 (0.273) | 166 (0.344) | 0.017 | 0.715 | 0.543-0.942 |
| A | D | 110 (0.231) | 143 (0.296) | 0.022 | 0.714 | 0.535-0.954 |
| T | I | 130 (0.273) | 145 (0.300) | 0.352 | 0.875 | 0.662-1.158 |
| T | D | 106 (0.223) | 28 (0.059) | < 0.001 | 4.557 | 2.949-7.041 |
Figure 2Kaplan–Meier survival curve for 7- and 30-day mortality of patients with rs4291 (A and B) and rs4646994 (C and D)
(A and C) 7-day survival curves; (B and D) 30-day survival curves.
Univariate analysis for the risk factors for the 7- and 30-day mortality rates of patients with SS
| Factor | 7 Days | 30 Days | ||||
|---|---|---|---|---|---|---|
| Survival | Death | Survival | Death | |||
| Shock period | 5.91 ± 2.18 | 6.40 ± 2.08 | 0.608 | 5.59 ± 2.09 | 6.91 ± 2.08 | <0.001 |
| APACHE II score | 30.92 ± 12.26 | 37.62 ± 11.46 | 0.001 | 30.84 ± 12.63 | 34.97 ± 11.32 | 0.017 |
| SOFA score | 8.63 ± 2.72 | 10.84 ± 2.27 | <0.001 | 8.39 ± 2.74 | 10.43 ± 2.29 | <0.001 |
| rs4291 | ||||||
| AA compared with AT/TT | 59/ 137 | 0/42 | 0.018 | 57/108 | 2/71 | <0.001 |
| rs4646994 | ||||||
| DD compared with DI/II | 29 /167 | 23/19 | <0.001 | 20/145 | 32/41 | <0.001 |
| Serum ACE | 52.70 ± 6.28 | 57.76 ± 5.78 | <0.001 | 52.81 ± 6.22 | 55.36 ± 6.74 | <0.001 |
Multivariate analysis of the risk factors for mortality rates of patients with SS
| Factor | β | S.E.M. | Wald | OR | 95% CI | |
|---|---|---|---|---|---|---|
| APACHE II score | 0.008 | 0.015 | 0.134 | 0.714 | 1.006 | 0.976–1.036 |
| SOFA score | –0.238 | 0.07 | 11.469 | 0.001 | 0.788 | 0.687–0.905 |
| rs4291 | –2.465 | 0.897 | 7.544 | 0.006 | 0.085 | 0.015–0.494 |
| rs4646994 | 0.889 | 0.38 | 5.479 | 0.019 | 2.432 | 1.156–5.117 |
| Serum ACE | 0.07 | 0.031 | 5.065 | 0.024 | 1.073 | 1.009–1.140 |